Algen Biotechnologies vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 40)
Algen Biotechnologies logo

Algen Biotechnologies

EmergingHealthcare

General

AI drug discovery platform mapping functional gene networks for novel target identification; $12.63M from Viking Global and YC W20 applying computational genomics to decode disease biology.

AI VisibilityBeta
Overall Score
C40
Category Rank
#374 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
35
Perplexity
39
Gemini
41

About

Algen Biotechnologies is a San Francisco-based drug discovery company that builds computational platforms to decode functional gene networks — using machine learning and genomic data to map the relationships between genes, understand how gene interactions drive disease, and identify novel therapeutic targets that traditional drug discovery approaches miss because they analyze genes in isolation. Founded in 2018 by Chun Hao Huang and Christine Du and a Y Combinator W20 graduate, Algen raised $12.63 million total including a $9 million Seed VC-II round led by Viking Global Investors in February 2022.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

40
Overall Score
90
#374
Category Rank
#2
80
AI Consensus
83
stable
Trend
stable
35
ChatGPT
92
39
Perplexity
93
41
Gemini
89
41
Claude
96
44
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.